{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Soler-Espejo E"],"funding":["Autonomous Community of the Region of Murcia","Instituto de Salud Carlos III"],"pagination":["1431-1442"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12803541"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(2)"],"pubmed_abstract":["<h4>Introduction</h4>Atrial fibrillation (AF) carries residual thromboembolic and cardiovascular risk despite oral anticoagulation (OAC). The stress hyperglycaemia ratio (SHR), derived from admission glucose and glycated haemoglobin (HbA1c), integrates information on both acute glycaemic fluctuations and chronic glycaemic burden. SHR has been associated with adverse outcomes in high-risk populations, but its utility in stratifying residual risk in anticoagulated AF patients remains uncertain. This study evaluated SHR as a marker of thromboembolic and cardiovascular risk in this setting.<h4>Methods</h4>This prospective cohort study included consecutive AF outpatients initiating OAC between January 2016 and November 2021. SHR was calculated, and patients were stratified into low and high SHR"],"journal":["Diabetes, obesity & metabolism"],"pubmed_title":["Relation of the stress hyperglycaemia ratio to residual risk in anticoagulated patients with atrial fibrillation: A report from the prospective Murcia AF Project III cohort."],"pmcid":["PMC12803541"],"funding_grant_id":["PI21/00670","21919/JLI/22"],"pubmed_authors":["Soler-Espejo E","Sanchez-Salas JA","Rivera-Caravaca JM","Marin F","Roldan V","Lip GYH","Chen Y","Esteve-Pastor MA"],"additional_accession":[]},"is_claimable":false,"name":"Relation of the stress hyperglycaemia ratio to residual risk in anticoagulated patients with atrial fibrillation: A report from the prospective Murcia AF Project III cohort.","description":"<h4>Introduction</h4>Atrial fibrillation (AF) carries residual thromboembolic and cardiovascular risk despite oral anticoagulation (OAC). The stress hyperglycaemia ratio (SHR), derived from admission glucose and glycated haemoglobin (HbA1c), integrates information on both acute glycaemic fluctuations and chronic glycaemic burden. SHR has been associated with adverse outcomes in high-risk populations, but its utility in stratifying residual risk in anticoagulated AF patients remains uncertain. This study evaluated SHR as a marker of thromboembolic and cardiovascular risk in this setting.<h4>Methods</h4>This prospective cohort study included consecutive AF outpatients initiating OAC between January 2016 and November 2021. SHR was calculated, and patients were stratified into low and high SHR","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-06-11T05:00:32.398Z","creation":"2026-06-11T03:08:02.246Z"},"accession":"S-EPMC12803541","cross_references":{"pubmed":["41342100"],"doi":["10.1111/dom.70335"]}}